Mindful Steps 2.0: Promoting Physical Activity in Patients With COPD and HF

Sponsor
Beth Israel Deaconess Medical Center (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05934565
Collaborator
Brigham and Women's Hospital (Other), VA Boston Healthcare System (U.S. Fed), University of Michigan (Other)
136
1
2
48
2.8

Study Details

Study Description

Brief Summary

The goal of this fully-remote randomized controlled trial is to test the efficacy of Mindful Steps in facilitating physical activity compared to usual standard of care among 136 patients with COPD and/or HF. The main question it aims to answer is can this intervention promote physical activity as measured by daily step counts in sedentary patients with COPD and/or HF. Participants will be randomized (1:1 ratio) to receive either the Mindful Steps intervention or usual care for 12 months, with both arms receiving a Walking for Health education booklet.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Mindful Steps
N/A

Detailed Description

This is a 2-arm parallel remotely delivered RCT. A total of 136 participants with COPD and/or HF will be randomized in a 1:1 ratio to one of 2 arms in a pragmatic design: 1) Mindful Steps multi-modal intervention, or 2) usual care (including an education booklet on walking). Subjects will participate in the intervention for 12 months. Testing will occur at baseline, 3, 6, 12 (end intervention), and 15 months (post-intervention follow up) for all participants. Physical activity as measured by pedometer (i.e., daily step counts) at 12 months is the primary outcome to assess the efficacy of the Mindful Steps intervention. Secondary outcomes include cognitive-behavioral measures that may relate to behavior change in a conceptual model (self-efficacy, intrinsic motivation, mindful awareness/interoception) as well as patient-centered clinical outcomes (HRQL, dyspnea, fatigue, PA engagement, sedentary behavior).

Study Design

Study Type:
Interventional
Anticipated Enrollment :
136 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
2-arm parallel remotely delivered randomized controlled trial2-arm parallel remotely delivered randomized controlled trial
Masking:
Single (Outcomes Assessor)
Masking Description:
Testing will be facilitated by study staff who are blinded to treatment assignment.
Primary Purpose:
Treatment
Official Title:
Mindful Steps: Coupling Technology and Mind-Body Exercise to Facilitate Physical Activity in Chronic Cardiopulmonary Disease
Anticipated Study Start Date :
Jun 30, 2024
Anticipated Primary Completion Date :
Jun 30, 2028
Anticipated Study Completion Date :
Jun 30, 2028

Arms and Interventions

Arm Intervention/Treatment
Experimental: Mindful Steps

Multi-modal web intervention including: pedometer with individualized step-count goals, motivational and educational content, online community forum, mind-body videos (short themed clips that support walking, plus library of mind-body exercises), online group mind-body exercise classes, star incentive system; educational booklet

Behavioral: Mindful Steps
Integrated website, activity tracker, and mind-body training

No Intervention: Usual Care

Pragmatic usual care (standard care through participant's healthcare provider including pharmacological treatment and general advice for physical activity); educational booklet

Outcome Measures

Primary Outcome Measures

  1. Change in physical activity [baseline, months 3, 6, 12, and 15]

    Daily step counts will be measured as an objective proxy for physical activity using FitBit pedometers (FitBit Inspire 3)

Secondary Outcome Measures

  1. Change in self-efficacy [baseline, months 3, 6, 12, and 15]

    Exercise self-efficacy will be measured using the Self-Efficacy for Exercise Scale and the Self-Efficacy for Managing Chronic Disease Scale. The Self-Efficacy for Exercise Scale a 9-item validated scale; scores range from 9-28, with a higher score meaning more self-efficacy. The Self-Efficacy for Managing Chronic Disease Scale is a 6-item visual analog scale; scores range from 1-10, with a higher score indicating higher self-efficacy.

  2. Change in intrinsic motivation [baseline, months 3, 6, 12, and 15]

    Intrinsic motivation will be measured using the Intrinsic Motivation Inventory. This is a 22-item scale validated with four sub-scales: interest/enjoyment, perceived competence, perceived choice, and pressure/tension. A higher score is better, with a scoring range of 22-154.

  3. Qualitative inquiry [months 6 and 12]

    Half-hour semi-structured qualitative interviews guided by study staff will be conducted over video/phone in a random subset of 50 participants at the 6 and 12 month timepoints.

  4. Change in disease-specific quality-of-life [baseline, months 3, 6, 12, and 15]

    Disease-specific quality-of-life will be measured using St. George's Respiratory Questionnaire (SGRQ) and The Minnesota Living with Heart Failure Questionnaire (MLFHQ). The SGRQ is a 50-item instrument developed and validated in COPD and calculates four scores: symptomatology, activity, impacts and an overall metric; scores range from 0-100, with higher scores indicating more limitations. The MLFHQ is a 21-item instrument; total scores range from 0-105, with higher scores indicating poorer quality-of-life.

  5. Change in exercise engagement [baseline, months 3, 6, 12, and 15]

    Exercise engagement will be measured using the Community Healthy Activities Model Program for Seniors (CHAMPS) Physical Activity Questionnaire. This 41-item self-report questionnaire assesses engagement with physical activity, including frequency and duration, among older adults over the past 4 weeks. Separate scores are derived for physical activities of varying intensities. Frequency and estimated caloric expenditure are calculated per week for each of these physical activity categories, with higher scores indicating greater frequency and duration of exercise.

  6. Change in sedentary behaviors/time [baseline, months 3, 6, 12, and 15]

    Sedentary behaviors/time will be measured using online weekly exercise logs. These online weekly exercise logs will be used to assess frequency and categorize exercises.

  7. Change in dyspnea [baseline, months 3, 6, 12, and 15]

    Dyspnea is being measured using the UCSD Shortness of Breath Questionnaire - a 24 item questionnaire using a 6 point Likert scale; scores range from 0-120, with higher scores indicating greater dyspnea.

  8. Change in fatigue [baseline, months 3, 6, 12 and 15]

    Fatigue will be measured using the The Patient-Reported Outcome Measurement Information System (PROMIS) Fatigue Short Form 7a. Raw scores range from 7-35, and each raw score is translated into a standardized T-score, with higher T-scores representing greater fatigue.

  9. Change in mindful awareness [baseline, months 3, 6, 12 and 15]

    Mindful awareness will be measures using the Multidimensional Assessment of Interoceptive Awareness, consisting of 37 items (8 domains), each domain scored as the average score on a 6-point Likert.

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Clinical diagnosis of COPD (defined as cigarette smoking history > 10 pack-years, and either a ratio of FEV1 to forced vital capacity < 0.70 or chest CT evidence of emphysema) OR clinical diagnosis of HF syndrome (with left ventricular systolic dysfunction or preserved ejection fraction and New York Heart Association Class 1-3)

  • Medical clearance from provider to participate in an exercise program

  • Have an active email account; access to a computer device (desktop, laptop, tablet, or smartphone that supports the Fitbit app).

Exclusion Criteria:
  • COPD or HF exacerbation in the previous month

  • Inability to ambulate

  • Inability to collect at least 7 of 14 days of baseline step counts

  • Current participation in a cardiac or pulmonary rehabilitation program

Contacts and Locations

Locations

Site City State Country Postal Code
1 BIDMC Boston Massachusetts United States 02215

Sponsors and Collaborators

  • Beth Israel Deaconess Medical Center
  • Brigham and Women's Hospital
  • VA Boston Healthcare System
  • University of Michigan

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Gloria Y. Yeh, Director of Mind-Body Research, BIDMC General Medicine Division; Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center
ClinicalTrials.gov Identifier:
NCT05934565
Other Study ID Numbers:
  • R01AT012166-01A1
First Posted:
Jul 7, 2023
Last Update Posted:
Jul 7, 2023
Last Verified:
Jun 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Gloria Y. Yeh, Director of Mind-Body Research, BIDMC General Medicine Division; Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 7, 2023